Summary

Generation of Human Patient iPSC-derived Retinal Organoids to Model Retinitis Pigmentosa

Published: June 16, 2022
doi:

Summary

In this protocol, retinitis pigmentosa patient induced pluripotent stem cell (iPSC)-derived 3D retinal organoids were generated. Those organoids successfully recapitulated some clinical phenotypes of the retinitis pigmentosa disease.

Abstract

Retinitis pigmentosa (RP) is a rare and inherited retinal degenerative disease with a prevalence of approximately 1/4,000 people worldwide. The majority of RP patients have progressive photoreceptor degeneration leading to peripheral vision loss, night blindness, and finally, total blindness. To date, thousands of mutations in more than 90 genes have been reported to be associated with RP. Currently, there are few animal models available for all the affected genes and different types of mutations, which largely hampers the deciphering of the mechanisms underlying the gene/mutation pathology and limits treatment and drug development. Patient induced pluripotent stem cell (iPSC)-derived 3D retinal organoids (ROs) have provided a better system to model the human early-onset disease than cells and animals. In order to study RP, those patient-derived 3D retinal organoids were utilized to recapitulate the clinical phenotypes of RP. In the RP patient-derived ROs, Rhodopsin mislocalization was clearly displayed. Compared with other animal models, patient iPSC-derived retinal organoid models more closely recapitulated RP features and represent an ideal approach for investigating the disease pathogenesis and for drug development.

Introduction

Human retinal diseases, such as retinitis pigmentosa and age-related macular degeneration, are poorly understood due to the lack of appropriate experimental models1,2. Although the mouse retina is very similar to the human retina and is a powerful tool for studying the etiology of retinal degeneration, there are huge species differences between mice and humans3,4. For instance, the nuclear architecture of the photoreceptor cells in mice and humans is different, and the mouse retina does not possess a macula5,6. Induced pluripotent stem cell (iPSC) technology enables us to return the specialized cells of organisms to the initial pluripotent state through the "reprogramming" processes by combinations of transcription factors and/or compounds7,8,9,10. Those iPSCs have nearly unlimited division and proliferation ability and could develop into various types of cells. Recently, iPSC-derived 3D retinal organoids have been developed to model the early events of human retinal development and to delineate the pathophysiology of human retinal diseases11,12,13,14,15. Retinal organoids have many advantages: (1) they can be used to recapitulate in vivo retinal development and disease pathogenesis; (2) they can be used for high-throughput drug screening and preclinical trials of gene therapy; and (3) they can be used as preclinical evaluations of treatment options for retinal degenerative diseases16,17.

One objective of this project was to study the pathogenesis of retinal pigmentosa (RP), a disease remaining incurable because of its extreme heterogeneity18. To date, over 90 genes have been identified to be associated with RP19,20. The RPGR gene, which is considered one of the most prevalent causative genes of RP15, accounts for approximately 16% of all RP4,21,22. iPSCs carrying a frameshift mutation in the RPGR gene have been successfully generated and differentiated into organized and stratified 3D retinal organoids14. By utilizing these organoids, abnormal photoreceptor layer morphology and the dislocation of opsins in photoreceptors were observed.

Altogether, a step-by-step and approachable protocol is described in detail here on how to generate patient-derived 3D retinal organoids23,24. Those organoids successfully recapitulated some clinical phenotypes of the disease. This provides an encouraging model to study retinal development and disease mechanisms, for therapeutic screening, and to evaluate future preclinical gene therapy.

Protocol

The protocol follows the guidelines of Capital Medical University's human research ethics committee. 1. Cell culture and generation of iPSCs Choose RPGR patients for this study. Here, three patients, one familial carrier and three healthy controls, were used. Patient 1 possessed a mutation c.1685_1686delAT in exon 14 of the RPGR gene, patient 2 harbored a mutation c.2234_2235delGA in exon 15 of the RPGR gene, and patient 3 had a mutation c.2403_2404delAG in exo…

Representative Results

The schematic illustration describes the differentiation procedures to generate healthy and patient iPSC-derived retinal organoids (Figure 1). From iPSC to ROs, variations can be produced owing to several factors. The status of the iPSC is the determinant step of the RO generation. In addition, it is highly recommended that researchers should record every step, catalog, and lot number of all media so that the entire experiments are trackable. In Figure 2A, the i…

Discussion

Retinal organoids are 3D, laminated structures derived from hiPSCs or embryonic stem cells (ESCs) and feature as a very promising model to mimic the spatial and temporal patterns of human retinal development31,32. The ROs consist of various types of retinal cells, including photoreceptors, bipolar cells, ganglion cells, amacrine cells, horizontal cells, and Müller glia33. 2D culture cannot precisely mimic the orientation and developme…

Divulgazioni

The authors have nothing to disclose.

Acknowledgements

We thank M.S. Yan-ping Li and Zhuo-lin Liu for their technical support and helpful comments regarding the manuscript. This work was partly supported by the National Natural Science Foundation of China (82171470, 31871497, 81970838, Z20J00122), Beijing Municipal Natural Science Foundation (Z200014, 82125007), and National Key R&D Program of China (2017YFA0105300).

Materials

96 V-bottomed conical wells Sumitomo Bakelite MS-9096VZ
A-83–01 R&D Systems 2939/10
Adhesion microscope slides CITOtest 188105
Agarose Gene Tech 111760
Amaxa Nucleofector 2b Device Lonza AAB-1001 Transfection system
B-27 Thermo Fisher Scientific 17504044
bFGF R&D Systems 3718-FB
Blebbistatin Nuwacell Biotechnologies RP01008
Blood collection tube BD Vacutainer EDTA 366643
CHIR99021 TOCRIS 4423/10
Cover slides CITOGLAS 10212440C
cTarget hPSC Medium Nuwacell Biotechnologies RP01020
DAPI Invitrogen D-1306
DMEM/Ham’s F12 Gibco 10565-042
Donkey anti-mouse 488 Invitrogen A-21202
Donkey anti-rabbit 594 Invitrogen A-21207
EDTA Nuwacell Biotechnologies RP01007
Embedding medium FluorSaveTM Reagent 345789
EX-CYTE growth enhancement medium Sigma 811292 Growth enhancement medium
Fetal bovine serum Gibco 04-002-1A
Ficoll Sigma-Aldrich 26873-85-8 Density gradient medium
FLT3L Peprotech 300-19
GlutaMAX Life Technologies 35050-061 L-glutamine supplement
HA-100 STEMCELL Technologies 72482
Ham’s F12 Gibco 11765-054
hLIF Thermo Fisher Scientific AF-250-NA
Homogenizer EDEN lab D-130
IL-3 Peprotech 213-13
IL-6 Peprotech 200-06
Iscove’s Modified Dulbecco Medium Gibco 12440053
KnockOut Serum Replacement – Multi-Species Gibco A3181502 Serum replacement media
L/M-opsin Millipore ab5405
Monothioglycerol Sigma M6145
N-2 supplement Thermo Fisher Scientific 17502048
Nanodrop Spectrophotometer Thermo Fisher Scientific ND2000 Spectrophotometer
ncEpic 125x Supplement Nuwacell Biotechnologies RP01001-02 125x Supplement
ncEpic Basal Medium Nuwacell Biotechnologies RP01001-01 Basal hpsc medium
ncLaminin511 human recombinant protein Nuwacell Biotechnologies RP01025
PD0325901 STEMCELL Technologies 72182
Penicillin-streptomycin Gibco 15140-122
Recombinant human BMP4 R&D Systems 314-BP
Retinoic acid Sigma R2625
Rhodopsin Sigma O4886
RNeasy Mini Kit Qiagen 74104
RNeasy Mini Kit Qiagen 74104
sIL6-R Thermo Fisher Scientific RP-75602
StemSpan SFEM medium STEMCELL Technologies 09600
Taurine Sigma T8691
Trizol reagent Invitrogen 15596026
Vitronectin Nuwacell Biotechnologies RP01002
V-Lance knife Alcon Surgical 8065912001

Riferimenti

  1. Jin, Z. B., et al. Stemming retinal regeneration with pluripotent stem cells. Progress in Retinal and Eye Research. 69, 38-56 (2019).
  2. Lin, Q., et al. Generation of nonhuman primate model of cone dysfunction through in situ AAV-mediated CNGB3 ablation. Molecular Therapy. Methods & Clinical Development. 18, 869-879 (2020).
  3. Zhou, M., Liu, Y., Ma, C. Distinct nuclear architecture of photoreceptors and light-induced behaviors in different strains of mice. Translational Vision Science & Technology. 10 (2), 37 (2021).
  4. Zito, I., et al. RPGR mutation associated with retinitis pigmentosa, impaired hearing, and sinorespiratory infections. Journal of Medical Genetics. 40 (8), 609-615 (2003).
  5. Solovei, I., et al. Nuclear architecture of rod photoreceptor cells adapts to vision in mammalian evolution. Cell. 137 (2), 356-368 (2009).
  6. Volland, S., Esteve-Rudd, J., Hoo, J., Yee, C., Williams, D. S. A Comparison of some organizational characteristics of the mouse central retina and the human macula. PLoS One. 10 (4), 0125631 (2015).
  7. Takahashi, K., Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126 (4), 663-676 (2006).
  8. Han, J. W., Yoon, Y. S. Induced pluripotent stem cells: Emerging techniques for nuclear reprogramming. Antioxidants & Redox Signaling. 15 (7), 1799-1820 (2011).
  9. Kim, J. S., Choi, H. W., Choi, S., Do, J. T. Reprogrammed pluripotent stem cells from somatic cells. International Journal of Stem Cells. 4 (1), 1-8 (2011).
  10. Li, Y. P., Liu, H., Jin, Z. B. Generation of three human iPSC lines from a retinitis pigmentosa family with SLC7A14 mutation. Stem Cell Research. 49, 102075 (2020).
  11. Capowski, E. E., et al. Reproducibility and staging of 3D human retinal organoids across multiple pluripotent stem cell lines. Development. 146 (1), 171686 (2019).
  12. Pan, D., et al. COCO enhances the efficiency of photoreceptor precursor differentiation in early human embryonic stem cell-derived retinal organoids. Stem Cell Research & Therapy. 11 (1), 366 (2020).
  13. Liu, H., et al. Human embryonic stem cell-derived organoid retinoblastoma reveals a cancerous origin. Proceedings of the National Academy of Sciences of the United States of America. 117 (52), 33628-33638 (2020).
  14. Deng, W. L., et al. Gene correction reverses ciliopathy and photoreceptor loss in iPSC-derived retinal organoids from retinitis pigmentosa patients. Stem Cell Reports. 10 (4), 1267-1281 (2018).
  15. Gao, M. L., et al. Patient-specific retinal organoids recapitulate disease features of late-onset retinitis pigmentosa. Frontiers in Cell and Developmental Biology. 8, 128 (2020).
  16. Del Amo, E. M., et al. Pharmacokinetic aspects of retinal drug delivery. Progress in Retinal and Eye Research. 57, 134-185 (2017).
  17. Aasen, D. M., Vergara, M. N. New drug discovery paradigms for retinal diseases: A focus on retinal organoids. Journal of Ocular Pharmacology and Therapeutics. 36 (1), 18-24 (2020).
  18. Hartong, D. T., Berson, E. L., Dryja, T. P. Retinitis pigmentosa. Lancet. 368 (9549), 1795-1809 (2006).
  19. Anasagasti, A., Irigoyen, C., Barandika, O., Lopez de Munain, A., Ruiz-Ederra, J. Current mutation discovery approaches in Retinitis Pigmentosa. Vision Research. 75, 117-129 (2012).
  20. Daiger, S. P., Bowne, S. J., Sullivan, L. S. Genes and mutations causing autosomal dominant retinitis pigmentosa. Cold Spring Harbor Perspectives in Medicine. 5 (10), 017129 (2014).
  21. Kortum, F., et al. X-linked retinitis pigmentosa caused by non-canonical splice site variants in RPGR. International Journal of Molecular Sciences. 22 (2), 850 (2021).
  22. Megaw, R. D., Soares, D. C., Wright, A. F. RPGR: Its role in photoreceptor physiology, human disease, and future therapies. Experimental Eye Research. 138, 32-41 (2015).
  23. Li, Y. P., Deng, W. L., Jin, Z. B. Modeling retinitis pigmentosa through patient-derived retinal organoids. STAR Protocols. 2 (2), 100438 (2021).
  24. Liu, H., Hua, Z. Q., Jin, Z. B. Modeling human retinoblastoma using embryonic stem cell-derived retinal organoids. STAR Protocols. 2 (2), 100444 (2021).
  25. Zhang, X. H., Xie, Y., Xu, K., Li, Y. Generation of an induced pluripotent stem cell line BIOi002-A from a patient with autosomal dominant optic atrophy. Stem Cell Research. 53, 102278 (2021).
  26. Nakano, T., et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell. 10 (6), 771-785 (2012).
  27. Kuwahara, A., et al. Generation of a ciliary margin-like stem cell niche from self-organizing human retinal tissue. Nature Communication. 6, 6286 (2015).
  28. Cowan, C. S., et al. Cell types of the human retina and its organoids at single-cell resolution. Cell. 182 (6), 1623-1640 (2020).
  29. Eldred, K. C., et al. Thyroid hormone signaling specifies cone subtypes in human retinal organoids. Science. 362 (6411), (2018).
  30. Kumar, R., et al. A high-throughput method for illumina RNA-seq library preparation. Frontiers in Plant Science. 3, 202 (2012).
  31. Fligor, C. M., et al. Three-dimensional retinal organoids facilitate the investigation of retinal ganglion cell development, organization and neurite outgrowth from human pluripotent stem cells. Scientific Reports. 8 (1), 14520 (2018).
  32. Morizur, L., Herardot, E., Monville, C., Ben M’Barek, K. Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration. Molecular and Cellular Neurosciences. 107, 103523 (2020).
  33. Bhatt, L., Groeger, G., McDermott, K., Cotter, T. G. Rod and cone photoreceptor cells produce ROS in response to stress in a live retinal explant system. Molecular Vision. 16, 283-293 (2010).
  34. O’Hara-Wright, M., Gonzalez-Cordero, A. Retinal organoids: A window into human retinal development. Development. 147 (24), (2020).
  35. Xue, Y., et al. Retinal organoids long-term functional characterization using two-photon fluorescence lifetime and hyperspectral microscopy. Frontiers in Cellular Neurosciences. 15, 796903 (2021).
  36. Colombo, L., et al. Comparison of 5-year progression of retinitis pigmentosa involving the posterior pole among siblings by means of SD-OCT: A retrospective study. BMC Ophthalmology. 18 (1), 153 (2018).
  37. Ferrari, S., et al. Retinitis pigmentosa: Genes and disease mechanisms. Current Genomics. 12 (4), 238-249 (2011).
  38. Shintani, K., Shechtman, D. L., Gurwood, A. S. Review and update: Current treatment trends for patients with retinitis pigmentosa. Optometry. 80 (7), 384-401 (2009).
  39. Wang, A. L., Knight, D. K., Vu, T. T., Mehta, M. C. Retinitis pigmentosa: Review of current treatment. International Ophthalmology Clinics. 59 (1), 263-280 (2019).
  40. Daiger, S. P., Sullivan, L. S., Bowne, S. J. Genes and mutations causing retinitis pigmentosa. Clinical Genetics. 84 (2), 132-141 (2013).
  41. Parfitt, D. A., et al. Identification and correction of mechanisms underlying inherited blindness in human iPSC-derived optic cups. Cell Stem Cell. 18 (6), 769-781 (2016).
  42. Shimada, H., et al. In vitro modeling using ciliopathy-patient-derived cells reveals distinct cilia dysfunctions caused by CEP290 mutations. Cell Reports. 20 (2), 384-396 (2017).
  43. Deretic, D., Wang, J. Molecular assemblies that control rhodopsin transport to the cilia. Vision Research. 75, 5-10 (2012).
  44. Rao, K. N., Li, L., Anand, M., Khanna, H. Ablation of retinal ciliopathy protein RPGR results in altered photoreceptor ciliary composition. Scientific Reports. 5, 11137 (2015).
  45. Zhang, X., Wang, W., Jin, Z. B. Retinal organoids as models for development and diseases. Cell Regeneration. 10 (1), 33 (2021).
  46. Zhang, X. H., Jin, Z. B. Patient iPSC-derived retinal organoids: Observable retinal diseases in-a-dish. Histology and Histopathology. 36 (7), 705-710 (2021).
This article has been published
Video Coming Soon
Keep me updated:

.

Citazione di questo articolo
Ma, C., Jin, K., Jin, Z. Generation of Human Patient iPSC-derived Retinal Organoids to Model Retinitis Pigmentosa. J. Vis. Exp. (184), e64045, doi:10.3791/64045 (2022).

View Video